Role of Atypical Chemokines and Chemokine Receptors Pathways in the Pathogenesis of COPD

Role of Atypical Chemokines and Chemokine Receptors Pathways in the Pathogenesis of COPD.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL: https://doi.org/10.2174/0929867327999200819145327
Journal or Publication Title: Current Medicinal Chemistry
Volume: 28
Number: 13
Page Range: pp. 2577-2653
Date: 19 August 2021
Divisions: UTS Centre for Inflammation
Depositing User: General Admin
Identification Number: 10.2174/0929867327999200819145327
ISSN: 09298673
Date Deposited: 10 Oct 2021 09:37
Abstract:

Chronic obstructive pulmonary disease (COPD) represents a heightened inflammatory response in the lung generally resulting from tobacco smoking-induced recruitment and activation of inflammatory cells and/or activation of lower airway structural cells. Several mediators can modulate activation and recruitment of these cells, particularly those belonging to the chemokines (conventional and atypical) family. There is emerging evidence for complex roles of atypical chemokines and their receptors (such as high mobility group box 1 (HMGB1), antimicrobial peptides, receptor for advanced glycosylation end products (RAGE) or toll-like receptors (TLRs)) in the pathogenesis of COPD, both in the stable disease and during exacerbations. Modulators of these pathways represent potential novel therapies for COPD and many are now in preclinical development. Inhibition of only a single atypical chemokine or receptor may not block inflammatory processes because there is redundancy in this network. However, there are many animal studies that encourage studies for modulating the atypical chemokine network in COPD. Thus, few pharmaceutical companies maintain a significant interest in developing agents that target these molecules as potential antiinflammatory drugs. Antibody-based (biological) and small molecule drug (SMD)-based therapies targeting atypical chemokines and/or their receptors are mostly at the preclinical stage and their progression to clinical trials is eagerly awaited. These agents will most likely enhance our knowledge about the role of atypical chemokines in COPD pathophysiology and thereby improve COPD management.

Keywords: Airway inflammation; alveolar macrophages; atypical chemokine receptors; atypical chemokines; chronic obstructive pulmonary disease; lymphocytes; small airways..

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Creators:
Creators
Email
Nucera, Francesco
UNSPECIFIED
Lo Bello, Federica
UNSPECIFIED
Shen, Sj S.
UNSPECIFIED
Ruggeri, Paolo
UNSPECIFIED
Coppolino, Irene
UNSPECIFIED
Di Stefano, Antonino
UNSPECIFIED
Stellato, Cristiana
UNSPECIFIED
Casolaro, Vincenzo
UNSPECIFIED
Hansbro, Phil M.
UNSPECIFIED
Adcock, Ian M.
UNSPECIFIED
Caramori, Gaetano
UNSPECIFIED
Last Modified: 10 Oct 2021 09:37
URI: https://eprints.centenary.org.au/id/eprint/1133

Actions (login required)

View Item View Item